Table 1

Associations of MARS expression with clinical characteristics and selected biological markers of BC

CharacteristicsNMARS expression (%)χ2 P value
Low or noHigh
Age (years)0.4120.814
 ≤402712 (44.4)15 (55.6)
 40–607531 (41.3)44 (58.7)
 ≥604019 (47.5)21 (52.5)
Tumour size (cm)0.8100.368
 ≤26124 (39.3)37 (60.7)
 >28138 (46.9)43 (53.1)
Tumour grade8.5060.014*
 I3219 (59.4)13 (40.6)
 II6330 (47.6)33 (52.4)
 III4713 (27.7)34 (72.3)
ER status0.5910.442
 Negative3915 (38.5)24 (61.5)
 Positive10347 (45.6)56 (54.3)
PR status1.4270.232
 Negative6324 (38.1)39 (61.9)
 Positive7938 (48.1)41 (51.9)
HER-2 status6.9620.008*
 Negative9850 (51.0)48 (49.0)
 Positive4412 (27.3)32 (72.2)
Ki-67 (%)5.9380.015*
 <206636 (54.5)30 (45.5)
 ≥207626 (34.2)50 (65.8)
Molecular classification10.5650.014*
 Luminal A4026 (65.0)14 (35.0)
 Luminal B6321 (33.3)42 (66.7)
HER-2 overexpression135 (38.5)8 (61.5)
 TNBC2610 (38.5)16 (61.5)
Histological types0.4300.806
 Ductal11350 (44.2)63 (55.8)
 Lobular157 (46.7)8 (53.3)
 Others145 (35.7)9 (64.3)
N stage5.0540.025*
 N06535 (53.8)30 (46.2)
 N1+2+37727 (35.1)50 (64.9)
TNM stage8.0430.018*
 Stage I4025 (62.5)15 (37.5)
 Stage II6022 (36.7)38 (63.3)
 Stages III and IV4215 (35.7)27 (64.3)
  • *P<0.05.

  • BC, breast cancer; ER, oestrogen receptor; HER-2, human epidermal growth factor receptor 2; MARS, methionyl–tRNA synthetase; PR, progesterone receptor; TNM, tumour, node, metastasis.